Dr Reddy's Srikakulam plant gets 1 observation from USFDA

Image
Press Trust of India New Delhi
Last Updated : Jun 16 2017 | 8:48 PM IST
Drug firm Dr Reddy's Laboratories today said the US health regulator has issued one observation after the inspection of a unit of its Srikakulam formulations facility.
The "audit of our formulations Srikakulam Plant (SEZ) Unit I, Andhra Pradesh, by the United States Food and Drug Administration (USFDA) has been completed today", Dr Reddy's Laboratories said in a filing to BSE.
The company has been issued a Form 483 with one observation, which it is addressing, it added.
Dr Reddy's Laboratories, however, did not disclose details about the observation.
As per the USFDA, an "FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts".
It notifies the company's management of objectionable conditions.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 16 2017 | 8:48 PM IST

Next Story